KalVista Pharmaceuticals (KALV) Cash & Equivalents Growth (1y) (2015 - 2025)
KalVista Pharmaceuticals (KALV) Cash & Equivalents Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 290.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 290.30% |
| Apr 30, 2025 | 314.03% |
| Oct 31, 2024 | -27.89% |
| Jul 31, 2024 | -35.54% |
| Apr 30, 2024 | -43.47% |
| Jan 31, 2024 | -72.89% |
| Oct 31, 2023 | 49.45% |
| Jul 31, 2023 | 30.49% |
| Apr 30, 2023 | 82.99% |
| Jan 31, 2023 | 86.61% |
| Oct 31, 2022 | -17.01% |
| Jul 31, 2022 | -21.68% |
| Apr 30, 2022 | -39.26% |
| Jan 31, 2022 | 157.10% |
| Oct 31, 2021 | 187.44% |
| Jul 31, 2021 | 168.36% |
| Apr 30, 2021 | 220.43% |
| Jan 31, 2021 | -4.77% |
| Oct 31, 2020 | -25.53% |
| Jul 31, 2020 | -40.17% |